Baron Capital sees long-term value in Guardant Health despite Q1 2026 fund underperformance
The Baron Health Care Fund declined in the first quarter, yet the firm maintains a bullish stance on Guardant Health's growth trajectory driven by its liquid biopsy technology and colorectal cancer screening initiatives.
Baron Capital has reaffirmed its conviction in Guardant Health within its Q1 2026 investor letter for the Baron Health Care Fund. While the fund reported a 6.97 per cent decline in the quarter, trailing the broader Russell 3000 Index, the investment manager specifically singled out the precision oncology company as a key holding with significant long-term potential. The correspondence notes that the fund's recent underperformance was driven by disappointing stock selection rather than a lack of faith in the healthcare sector's fundamentals.
The letter details Guardant Health's robust financial performance, citing 33 per cent revenue growth in 2025 and a market capitalisation of $11.49 billion. Management has set ambitious targets for the coming year, projecting revenue expansion between 27 per cent and 30 per cent for 2026. This growth outlook is anchored in the company's flagship liquid biopsy test, Guardant360, which is used to inform therapy selection for patients with advanced stage solid tumours without the need for invasive biopsies.
A central pillar of the investment thesis is the company's expanding colorectal cancer screening platform, Shield. Baron Capital notes that adoption of Shield has already exceeded Wall Street analyst expectations. To capitalise on an estimated $18 billion annual market opportunity, the company plans to double its sales force from 300 to 600 staff members this year. Additionally, Guardant has partnered with Quest Diagnostics to provide expanded access to physicians and patients for the platform.
Looking beyond colorectal cancer, the investor letter highlights Guardant Health's strategic roadmap to diversify its offerings. The company intends to launch Guardant Reveal Ultra, a tissue-informed assay, later this year. Furthermore, management expects to utilise the Shield platform to expand into lung cancer screening and multi-cancer detection in the future. These initiatives are supported by a balance sheet featuring $1.3 billion in cash at the end of 2025, providing the liquidity needed to execute these growth plans.
Despite the positive outlook from Baron Capital, the stock has faced recent volatility. As of May 1, 2026, Guardant Health shares closed at $87.60, recording a one-month return of minus 2.30 per cent. However, over the past 52 weeks, the shares have gained 98.86 per cent. The firm acknowledges that while Guardant Health offers substantial potential, it currently ranks lower than certain artificial intelligence stocks on its list of 40 most popular holdings for 2026 due to perceived upside and downside risk profiles.
Hedge fund sentiment remains generally positive, with 62 portfolios holding the stock at the end of the fourth quarter, an increase from 50 in the previous period. Nevertheless, Baron Capital maintains that the company has a long runway for future growth, anticipating significant free cash flow generation in the out years as the business accelerates. The firm concludes that despite short-term market fluctuations, Guardant Health remains a critical component of the healthcare investment strategy.
